Noxopharm has replied to the USPTO requirement to refine their patent applicationIMPROVEMENTS IN CANCER TREATMENT by defining Idronoxil as their 'elected species'.
Any claims for other species that were withdrawn can be pursued in subsequent applications.
Moving forward, as expected. Harvett will no doubt take exception, but who cares?
Patent Update
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.017(14.8%) |
Mkt cap ! $28.63M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 9.8¢ | $70.79K | 680.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25356 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 240399 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |